“…Studies on treatment outcomes of sclerotherapy/embolization often focus on a specific CVM subtype, a specific anatomical location, or a specific agent, and the definition of a successful treatment outcome varies, all of which limits comparability. In recent studies on pediatric patients, a complete response was reported in 11-89% of the patients and improvement in 57-100% [34,48,49,51,54,69,70]. In LMs, bleomycin seems to be the most effective agent, and macrocystic lesions often showed a better response than microcystic and/or mixed lesions [49,53,70].…”